Results 61 to 70 of about 82,604 (202)

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

Nature Communications
Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types. Currently, there are no established targeted therapies with proven efficacy for cancers with non-V600E BRAF mutations.
April A. N. Rose, Jennifer Maxwell, Emmanuelle Rousselle, Chantel L. Mukonoweshuro, Islam E. Elkholi, Melody Riaud, Marco Biondini, Erica Cianfarano, Isabel Soria-Bretones, Chantal Tobin, Meghan McGuire, Rhoda W. Y. Law, Andrew J. Elia, Ben X. Wang, Ian King, Tong Zhang, Trevor J. Pugh, Zaid Saeed Kamil, Marcus Butler, Frances A. Shepherd, Natasha B. Leighl, Albiruni Abdul Razak, Aaron Hansen, Samuel D. Saibil, Philippe L. Bedard, Peter M. Siegel, Lillian L. Siu, David W. Cescon, Anna Spreafico   +28 more
doaj   +1 more source

Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies

Clinical Ophthalmology, 2020
Anastasia Gkiala,1 Sotiria Palioura2 1National and Kapodistrian University of Athens School of Medicine, Athens, Greece; 2Athens Vision Eye Institute, Athens, GreeceCorrespondence: Sotiria PaliouraAthens Vision Eye Institute, 328-330 Syngrou Ave ...
Gkiala A, Palioura S
doaj  

The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]

, 2015
The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva, A Snyder, Adam Bloomfield, AM Broadbent, Andrew Furness, Anna Wilkins, C Nieder, C Nieder, D Mathieu, D Rades, E Weltman, FE Harrell Jr, GV Long, J Larkin, J Lorenzoni, J Raizer, James Larkin, JG Lorenzoni, K Margolin, Kevin Harrington, LE Gaspar, M Staudt, MA Hofmann, Nuria Porta, P Royston, PC Tumeh, PW Sperduto, PW Sperduto, R Dummer, R Fisher, R Partl, Richard W Corbett, SL Morris, Stephen Morris, T Serizawa, TK Eigentler, Zohra Ali   +36 more
core   +2 more sources

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. [PDF]

, 2014
BackgroundIn melanoma, dysregulation of the MAPK pathway, usually via BRAF(V600) or NRAS(Q61) somatic mutations, leads to constitutive ERK signaling.
Atefi, Mohammad S, Avarappatt, Geetha, Avramis, Earl, Cerniglia, Michael, Comin-Anduix, Begonya, Foulad, David, Graeber, Thomas G, Lassen, Amanda, Lo, Roger S, Ribas, Antoni, Robert, Lidia, Samatar, Ahmed, Tsoi, Jennifer, Wong, Deborah JL   +13 more
core   +1 more source

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. [PDF]

, 2017
Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis.
Aplin, Andrew E., Cheng, Hanyin, Chua, Vivian, Davies, Michael A., Kageyama, Ken, Liao, Connie, Purwin, Timothy J., Sato, Takami, Terai, Mizue   +8 more
core   +2 more sources

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

Biomarker Research, 2017
Alternate BRAF splicing is the most common mechanism of acquired resistance to BRAF inhibitor treatment in melanoma. Recently, alternate BRAF exon 4–8 splicing was shown to involve an intronic mutation, located 51 nucleotides upstream of BRAF exon 9 ...
Gulietta M. Pupo, Suzanah C. Boyd, Carina Fung, Matteo S. Carlino, Alexander M. Menzies, Bernadette Pedersen, Peter Johansson, Nicholas K. Hayward, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos   +11 more
doaj   +1 more source

Anorectal Melanoma [PDF]

, 2018
Anorectal melanoma (AM) is a rare malignancy, characterized by aggressive behavior and a poor prognosis. AM is more frequent in female patients aged over 50 years.
Dario Didona, Giovanni Paolino, Giulia Macrì, Santo Raffaele Mercuri., Stefano Calvieri   +4 more
core   +1 more source

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma

Neoplasia: An International Journal for Oncology Research, 2020
BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acquire the resistance to BRAF inhibitors after several months of treatment.
Mai-Huong Thi Nguyen, Chen-Huan Lin, Szu-Mam Liu, Azusa Miyashita, Hironobu Ihn, Hsuan Lin, Chi Hou Ng, Jen-Chieh Tsai, Ming-Hong Chen, Mu-Shiun Tsai, In-Yu Lin, Shu-Chen Liu, Long-Yuan Li, Satoshi Fukushima, Jean Lu, Nianhan Ma   +15 more
doaj   +1 more source

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? [PDF]

, 2019
Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent.
Badalamenti G., Bazan V., Fanale D., Fulfaro F., Incorvaia L., Iovanna J. L., Olive D., Rinaldi G., Russo A., Swayden M., Terruso L., Vincenzi B.   +11 more
core   +1 more source

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance

Journal of Skin Cancer, 2011
Since the initial discovery that a subset of patients with cutaneous melanoma harbor BRAF mutations, substantial research has been focused on determining the pathologic consequences of BRAF mutations, optimizing diagnostic techniques to identify these ...
Ryan J. Sullivan, Keith T. Flaherty
doaj   +1 more source